(Q44896736)

English

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial (English)

1 reference

Europe PubMed Central

7 December 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

Johan G. Eriksson

3

1 reference

Europe PubMed Central

7 December 2017

author name string

Burkhard Göke

1

1 reference

Europe PubMed Central

7 December 2017

Baptist Gallwitz

2

1 reference

Europe PubMed Central

7 December 2017

Åsa Hellqvist

4

1 reference

Europe PubMed Central

7 December 2017

Ingrid Gause-Nilsson

5

1 reference

Europe PubMed Central

7 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2013

1 reference

Europe PubMed Central

7 December 2017

International Journal of Clinical Practice

1 reference

Europe PubMed Central

7 December 2017

67

1 reference

Europe PubMed Central

7 December 2017

4

1 reference

Europe PubMed Central

7 December 2017

307-316

1 reference

Europe PubMed Central

7 December 2017

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Altered Hierarchy of Protective Responses Against Severe Hypoglycemia in Normal Aging in Healthy Men

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12119

21 January 2018

Identifiers

10.1111/IJCP.12119

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44896736&oldid=2056153750"